用神经调节来增强动词命名疗法减缓了初级渐进性失言症中语言丧失的速度
Shannon M Sheppard1,2, Emily B Goldberg2, Rajani Sebastian3
1Department of Speech and Hearing Sciences, University of Washington, Seattle.
American journal of speech-language pathology
|December 12, 2024
概括
动词网络强化治疗 (VNeST) 与跨直流刺激 (tDCS) 结合,改善了初级渐进性失语症 (PPA) 的词查找. 虽然VNeST单独帮助训练有素的动词,但添加tDCS增强了未经训练的动词回忆和其他语言技能.
科学领域:
- 神经语言学是一种神经语言学.
- 认知神经科学 认知神经科学
- 语音语言病理学 语言病理学
背景情况:
- 初级渐进性失言症 (PPA) 是一种神经退行性疾病,影响语言能力.
- 难以找到单词 (贫血) 是PPA的常见和衰弱的症状.
- 目前针对PPA症状的治疗方法,特别是贫血,对持续改善的有效性有限.
研究的目的:
- 评估Verb网络增强治疗 (VNeST) 结合左下额头经直流刺激 (tDCS) 在PPA患者的疗效.
- 为了比较VNeST + 真实tDCS与VNeST + 假刺激对PPA患者各种语言测量的影响.
主要方法:
- 一个双盲,在主体内,假冒控制的交叉设计与八名PPA参与者被采用.
- 参与者经历了两个治疗阶段:VNeST与真正的tDCS和VNeST与假刺激,每一个由15个1小时的会议.
- 语言能力,包括训练/未训练的动词命名,句子制作/理解和话语,在基线和治疗后1周和8周被评估.
主要成果:
- 在治疗后1周,VNeST在实际的tDCS和假的条件下显著改善了训练的动词命名和话语完整性.
- 经直流刺激 (tDCS) 增强导致未经训练的动词命名,句子生成和理解的普遍改善,持续至治疗后8周.
- 语言能力,特别是未经训练的动词命名和句子理解能力,在没有tDCS的VNeST时下降.
结论:
- 将VNeST与tDCS结合起来,有望在患有PPA的个体中增强词查找和其他语言功能.
- 单靠VNeST可以改善训练有素的动词的命名,但它对未经训练的单词的好处可能不会在没有神经调节的情况下持续下去.
- 需要使用更大的样本大小进行进一步的研究,以确认VNeST和tDCS在PPA治疗中的治疗潜力.
相关概念视频
Long-term Potentiation
2.7K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
Hebbian LTP
LTP can occur when...
2.7K
Alzheimer's Disease: Treatment
163
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
163
Parkinson's Disease: Treatment
219
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
219
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
96
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
96


